NCT00741897

Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis

A Monitored Release Study On The Efficacy And Safety of Fexofenadine (Telfast®) 30mg Pediatric Tablets On Filipino Children Aged 6 To 11 for The Relief of Perennial And Intermittent Allergic Rhinitis.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 264 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 6 Years – 11 Years
• Healthy volunteers: Not accepted

Summary

To determine the safety and efficacy of Fexofenadine (Telfast®) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic rhinitis.

Conditions

• Rhinitis, Allergic, Perennial

Interventions

Type	Name	Description
DRUG	Fexofenadine	Fexofenadine: One 30 mg Tablet once daily for two weeks

Timeline

• Start date: 2002-03-01
• Primary completion: 2003-12-01
• First posted: 2008-08-26
• Last updated: 2009-09-15

Locations

1 site across 1 country: Philippines